Peer-reviewedCC BY 4.0Frontiers in Immunology
Editorial: Improving efficacy and expanding the reach of T-cell therapeutics for solid tumors: an end-to-end perspective
- 1BioNTech US, Inc.
- 2AstraZeneca
- 3Earle A. Chiles Research Institute, a division of Providence Cancer Institute
Related
- Editorial: Expanding the therapeutic dose range of cannabinoid-based therapy
- Editorial: The expanding spectrum of hemophagocytic lymphohistiocytosis: pathogenic mechanisms and therapeutic implications
- Editorial: Evolution of antimicrobial resistance in intracellular bacterial pathogens: a genomic and historical perspective
- Improving allergic rhinitis symptoms through nutrition as an adjunct: a systematic review and meta-analysis on the efficacy of dietary supplements
- Efficacy of statistical and design interventions for improving reproducibility in biomedical research
BibTeX
@article{juneja2026editorial,
title = {{Editorial: Improving efficacy and expanding the reach of T-cell therapeutics for solid tumors: an end-to-end perspective}},
author = {Vikram R. Juneja and Gavin M. Bendle and Eric Tran and Marit M. van Buuren},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.2038020},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2038020/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Editorial: Improving efficacy and expanding the reach of T-cell therapeutics for solid tumors: an end-to-end perspective
AU - Vikram R. Juneja
AU - Gavin M. Bendle
AU - Eric Tran
AU - Marit M. van Buuren
PY - 2026
DA - 2026/11/16
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2038020
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2038020/full
SN - 1664-3224
ER -